UNITED STATES SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
[X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT 1934
For the quarterly period ended March 31, 2014
Commission File No. 0-22179
GUIDED THERAPEUTICS, INC.
(Exact Name of Registrant as Specified in Its Charter)
|
Delaware (State or other jurisdiction of incorporation or organization) |
58-2029543 (I.R.S. Employer Identification No.) |
|
5835 Peachtree Corners East, Suite D Norcross, Georgia 30092 (Address of principal executive offices) (Zip Code) |
(770) 242-8723
(Registrant’s telephone number, including area code)
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days: Yes [ ] No [ X ]
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes [ X ] No [ ]
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-12 of the Exchange Act (Check one):
Large Accelerated filer _____ Accelerated filer ____ Non-accelerated filer_____ Smaller Reporting Company X
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.
Yes [ ] No [X]
As of May 8, 2014, the registrant had outstanding 72,172,331 shares of Common Stock.
| 1 |
GUIDED THERAPEUTICS, INC. AND SUBSIDIARY
INDEX
| Part I. Financial Information | 3 |
| Item 1. Financial Statements | 3 |
| Condensed Consolidated Balance Sheets (Unaudited) - | |
| March 31, 2014 and December 31, 2013 | 3 |
| Condensed Consolidated Statements of Operations (Unaudited) | |
| Three months ended March 31, 2014 and 2013 | 4 |
| Condensed Consolidated Statements of Cash Flows (Unaudited) | |
| Three months ended March 31, 2014 and 2013 | 5 |
| Notes to Condensed Consolidated Financial Statements (Unaudited) | 6 |
| Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations | 13 |
| Item 3. Quantitative and Qualitative Disclosures About Market Risk | 16 |
| Item 4. Controls and Procedures | 16 |
| Part II. Other Information | 18 |
| Item 1. Legal Proceedings | |
| Item 1A. Risk Factors | 18 |
| Item 2. Unregistered Sale of Equity Securities and Use of Proceeds. | 18 |
| Item 3. Defaults Upon Senior Securities | 18 |
| Item 4. Mine Safety Disclosures | 18 |
| Item 5. Other Information | 18 |
| Item 6. Exhibits | 18 |
| Signatures | 19 |
| 2 |
PART I - FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
| GUIDED THERAPEUTICS, INC. AND SUBSIDIARY |
| CONDENSED CONSOLIDATED BALANCE SHEETS |
| (Unaudited, In Thousands) |
| AS OF | ||||||||
| ASSETS | March 31, 2014 | December 31, 2013 | ||||||
| CURRENT ASSETS: | ||||||||
| Cash and cash equivalents | $ | 50 | $ | 613 | ||||
| Accounts receivable, net of allowance for doubtful accounts of $18 at both March 31, 2014 and December 31, 2013 | 122 | 133 | ||||||
| Inventory, net of reserves of $120 and $184, at March 31, 2014 and December 31, 2013, respectively | 1,254 | 1,193 | ||||||
| Other current assets | 48 | 101 | ||||||
| Total current assets | 1,474 | 2,040 | ||||||
| Property and equipment, net | 807 | 920 | ||||||
| Other assets | 315 | 356 | ||||||
| Total noncurrent assets | 1,122 | 1,276 | ||||||
| TOTAL ASSETS | $ | 2,596 | $ | 3,316 | ||||
| LIABILITIES AND STOCKHOLDERS’ DEFICIT | ||||||||
| CURRENT LIABILITIES: | ||||||||
| Short-term notes payable, including related party | $ | 378 | $ | 35 | ||||
| Current portion of long-term debt | 111 | 109 | ||||||
| Accounts payable | 1,268 | 891 | ||||||
| Accrued liabilities | 997 | 723 | ||||||
| Deferred revenue | 6 | 14 | ||||||
| Total current liabilities | 2,760 | 1,772 | ||||||
| Warrants, at fair value | 1,007 | 1,548 | ||||||
| Long-term debt, net | 99 | 103 | ||||||
| Total long-term liabilities | 1,106 | 1,651 | ||||||
| TOTAL LIABILITIES | 3,866 | 3,423 | ||||||
| STOCKHOLDERS’ DEFICIT: | ||||||||
| Series B convertible preferred stock, $.001 par value; 3 shares authorized, 2 and 2 shares issued and outstanding as of March 31, 2014 and December 31, 2013, respectively (liquidation preference of $1.7 million and $2.1 million at March 31, 2014 and December 31, 2013, respectively) | 922 | 1,139 | ||||||
| Common stock, $.001 Par value; 145,000 shares authorized, 71,770 and 70,479 shares issued and outstanding as of March, 31 2014 and December 31, 2013, respectively | 72 | 71 | ||||||
| Additional paid-in capital | 102,503 | 101,840 | ||||||
| Treasury stock, at cost | (132 | ) | (132 | ) | ||||
| Accumulated deficit | (104,635 | ) | (103,025 | ) | ||||
| TOTAL STOCKHOLDERS’ DEFICIT | (1,270 | ) | (107 | ) | ||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT | $ | 2,596 | $ | 3,316 | ||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
| 3 |
| GUIDED THERAPEUTICS INC. AND SUBSIDIARY | ||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||
| (Unaudited, in Thousands Except Share and Per-Share Data) | ||||||||
| FOR THE THREE MONTHS ENDED MARCH 31, | ||||||||
| 2014 | 2013 | |||||||
| REVENUE: | ||||||||
| Contract and grant revenue | $ | 19 | $ | 167 | ||||
| Sales – devices and disposables | 122 | 132 | ||||||
| Cost of goods sold | 192 | 158 | ||||||
| Gross loss | (70 | ) | (26 | ) | ||||
| OPERATING EXPENSES: | ||||||||
| Research and development | 607 | 813 | ||||||
| Sales and marketing | 283 | 164 | ||||||
| General and administrative | 1,138 | 1,039 | ||||||
| Total operating expenses | 2,028 | 2,016 | ||||||
| Operating loss | (2,079 | ) | (1,875 | ) | ||||
| OTHER INCOME (EXPENSES): | ||||||||
| Other income | 2 | 75 | ||||||
| Interest expense | (27 | ) | (15 | ) | ||||
| Change in fair value of warrants | 542 | — | ||||||
| Total other income | 517 | 60 | ||||||
| LOSS FROM OPERATIONS | (1,562 | ) | (1,815 | ) | ||||
| PROVISION FOR INCOME TAXES | — | — | ||||||
| NET LOSS | $ | (1,562 | ) | $ | (1,815 | ) | ||
| PREFERRED STOCK DIVIDENDS | 48 | — | ||||||
| NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS | $ | (1,610 | ) | $ | (1,815 | ) | ||
| BASIC AND DILUTED NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS | $ | (0.02 | ) | $ | (0.03 | ) | ||
| WEIGHTED AVERAGE SHARES OUTSTANDING | 71,451 | 63,671 | ||||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
| 4 |
| GUIDED THERAPEUTICS INC. AND SUBSIDIARY | ||||||||
| CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS | ||||||||
| (Unaudited, in Thousands) | ||||||||
| FOR THE THREE MONTHS ENDED MARCH 31, | ||||||||
| 2014 | 2013 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES: | ||||||||
| Net loss | $ | (1,562 | ) | $ | (1,815 | ) | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||||||||
| Bad debt expense | — | 7 | ||||||
| Depreciation | 117 | 112 | ||||||
| Stock based compensation | 359 | 430 | ||||||
| Change in fair value of warrants | (541 | ) | — | |||||
| Changes in operating assets and liabilities: | ||||||||
| Inventory | (61 | ) | 85 | |||||
| Accounts receivable | 11 | (65 | ) | |||||
| Other current assets | 53 | (49 | ) | |||||
| Other assets | 41 | (30 | ) | |||||
| Accounts payable | 377 | 113 | ||||||
| Deferred revenue | (8 | ) | 25 | |||||
| Accrued liabilities | 255 | (126 | ) | |||||
| Total adjustments | 603 | 502 | ||||||
| Net cash used in operating activities | (959 | ) | (1,313 | ) | ||||
| CASH FLOWS FROM INVESTING ACTIVITIES: | ||||||||
| Additions to fixed assets | (4 | ) | (101 | ) | ||||
| Net cash used in investing activities | (4 | ) | (101 | ) | ||||
| CASH FLOWS FROM FINANCING ACTIVITIES: | ||||||||
| Proceeds from debt financing | 378 | — | ||||||
| Payments made on notes payable | (45 | ) | (169 | ) | ||||
| Proceeds from options and warrants exercised | 67 | 1,648 | ||||||
| Net cash provided by financing activities | 400 | 1,479 | ||||||
| NET CHANGE IN CASH AND CASH EQUIVALENTS | (563 | ) | 65 | |||||
| CASH AND CASH EQUIVALENTS, beginning of year | 613 | 1,044 | ||||||
| CASH AND CASH EQUIVALENTS, end of period | $ | 50 | $ | 1,109 | ||||
| SUPPLEMENTAL SCHEDULE OF: | ||||||||
| Cash paid for: | ||||||||
| Interest | $ | 8 | $ | 4 | ||||
| NONCASH INVESTING AND FINANCING ACTIVITIES: | ||||||||
| Conversion of accrued expenses into common stock / options | $ | 22 | $ | — | ||||
| Issuance of common stock as compensation | $ | — | $ | 463 | ||||
The accompanying notes are an integral part of these condensed consolidated financial statements.
| 5 |
GUIDED THERAPEUTICS, INC. AND SUBSIDIARY
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)
1. BASIS OF PRESENTATION
The accompanying unaudited condensed consolidated financial statements included herein have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“GAAP”) for interim financial reporting and with the instructions to Form 10-Q and Article 10 of Regulation S-X by Guided Therapeutics, Inc. (formerly SpectRx, Inc.), together with its wholly owned subsidiary InterScan, Inc., (“Interscan”) (formerly Guided Therapeutics, Inc.), collectively referred to herein as the “Company”. Accordingly, they do not include all information and footnotes required by GAAP for complete financial statements. These statements reflect adjustments, all of which are of a normal, recurring nature, and which are, in the opinion of management, necessary to present fairly the Company’s financial position as of March 31, 2014, results of operations for the three months ended March 31, 2014 and 2013, and cash flows for the three months ended March 31, 2014 and 2013. The results of operations for the three months ended March 31, 2014 are not necessarily indicative of the results for a full fiscal year. Preparing financial statements requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and disclosure of contingent assets and liabilities. Actual results could differ from those estimates. These financial statements should be read in conjunction with the financial statements and notes thereto included in the Company’s annual report on Form 10-K for the year ended December 31, 2013.
The Company's prospects must be considered in light of the substantial risks, expenses and difficulties encountered by entrants into the medical device industry. This industry is characterized by an increasing number of participants, intense competition and a high failure rate. The Company has experienced net losses since its inception and, as of March 31, 2014, it had an accumulated deficit of approximately $104.6 million. Through March 31, 2014, the Company has devoted substantial resources to research and development efforts. The Company does not have significant experience in manufacturing, marketing or selling its products. The Company's development efforts may not result in commercially viable products and it may not be successful in introducing its products. Moreover, required regulatory clearances or approvals may not be obtained. The Company's products may not ever gain market acceptance and the Company may not ever achieve levels of revenue to sustain further development costs and support ongoing operations or achieve profitability. The development and commercialization of the Company's products will require substantial development, regulatory, sales and marketing, manufacturing and other expenditures. The Company expects operating losses to continue through the foreseeable future as it continues to expend substantial resources to complete development of its products, obtain regulatory clearances or approvals and conduct further research and development.
Going Concern
The Company’s consolidated financial statements have been prepared and presented on a basis assuming it will continue as a going concern. The factors below raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might be necessary from the outcome of this uncertainty. Notwithstanding the foregoing, the Company believes it has made progress in recent years in stabilizing its financial situation by execution of multiyear contracts from Konica Minolta Opto, Inc., a subsidiary of Konica Minolta, Inc., a Japanese corporation based in Tokyo (“Konica Minolta”) and grants from the National Cancer Institute (“NCI”), while at the same time simplifying its capital structure and significantly reducing debt. However, the Company has replaced its prior agreements with Konica Minolta with a new licensing agreement, and therefore will no longer receive direct payments from Konica Minolta, and will have to pay a royalty to Konica Minolta should the Company sell any products licensed from Konica Minolta.
At March 31, 2014, the Company had negative working capital of approximately $1.3 million and the stockholders’ deficit was approximately $1.3 million, primarily due to recurring net losses from operations, deemed dividends on warrants and preferred stock, offset by proceeds from the exercise of options and warrants. In addition, the Company is past due on payroll tax liabilities totaling $200,000.
The Company’s capital-raising efforts are ongoing. If sufficient capital cannot be raised by the end of 2014, the Company has plans to curtail operations by reducing discretionary spending and staffing levels, and attempting to operate by only pursuing activities for which it has external financial support and additional NCI, NHI or other grant funding. However, there can be no assurance that such external financial support will be sufficient to maintain even limited operations or that the Company will be able to raise additional funds on acceptable terms, or at all. In such a case, the Company might be required to enter into unfavorable agreements or, if that is not possible, be unable to continue operations, and to the extent practicable, liquidate and/or file for bankruptcy protection.
| 6 |
The Company had warrants exercisable for approximately 11.6 million shares of its common stock outstanding at March 31,
2014, with exercise prices of $0.40, $0.68, $0.80 and $1.08 per share. Exercises of these warrants would generate a total of approximately $7.9 million in cash, assuming full exercise, although the Company cannot be assured that holders will exercise any warrants. Management may obtain additional funds through the private sale of preferred stock or debt securities, public and private sales of common stock, and grants, if available.
Assuming the Company receives FDA approval for its LuViva cervical cancer detection device in 2014, the Company currently anticipates an early 2015 product launch in the United States. Product launch outside the United States began in the second half of 2013.
2. SIGNIFICANT ACCOUNTING POLICIES
The Company’s significant accounting policies were set forth in the audited financial statements and notes thereto for the year ended December 31, 2013 included in its annual report on Form 10-K, filed with the Securities and Exchange Commission (“SEC”).
Use of Estimates
The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant areas where estimates are used include the allowance for doubtful accounts, inventory valuation and input variables for Black-Scholes, Monte Carlo simulations and Lattice Model calculations.
Principles of Consolidation
The accompanying consolidated financial statements, as of and for the quarter ended March 31, 2014, includes the accounts of Guided Therapeutics, Inc. and its wholly owned subsidiary.
Accounting Standards Updates
Newly effective accounting standards updates and those not effective until after March 31, 2014, are not expected to have a significant effect on the Company’s financial position or results of operations.
Cash Equivalents
The Company considers all highly liquid investments with an original maturity of three months or less when purchased to be a cash equivalent.
Concentration of Credit Risk
The Company, from time to time during the periods covered by these consolidated financial statements, may have bank balances in excess of its insured limits. Management has deemed this a normal business risk.
Inventory Valuation
All inventories are stated at lower of cost or market, with cost determined substantially on a “first-in, first-out” basis. Selling, general, and administrative expenses are not inventoried, but are charged to expense when purchased. At March 31, 2014 and December 31, 2013 our inventories were as follows (in thousands):
March 31, 2014 | December 31, 2013 | |||||||
| Raw materials | $ | 1,108 | $ | 1,013 | ||||
| Work in process | 209 | 268 | ||||||
| Finished goods | 57 | 96 | ||||||
| Inventory reserve | (120 | ) | (184 | ) | ||||
| Total | $ | 1,254 | $ | 1,193 |
| 7 |
Property and equipment
Property and equipment are recorded at cost. Depreciation is computed using the straight-line method over estimated useful lives of three to seven years. Leasehold improvements are depreciated at the shorter of the useful life of the asset or the remaining lease term. Depreciation expense is included in general and administrative expense on the statement of operations. Expenditures for repairs and maintenance are expensed as incurred.
Revenues
The majority of the Company’s revenues were from product sales of approximately $122,000, grants with NIH totaling approximately $13,000, as well as other income from royalties of approximately $5,000, for the three months ended March 31, 2014. Revenue for the same period in 2013, was from product sales of approximately $132,000, grants with NIH and NCI totaling approximately $97,000, as well as other income from royalty and miscellaneous receipts of approximately $70,000 for the three months ended March 31, 2013.
Accounts Receivable
The Company performs periodic credit evaluations of its customers’ financial condition and generally does not require collateral. The Company reviews all outstanding accounts receivable for collectability on a quarterly basis. An allowance for doubtful accounts is recorded for any amounts deemed uncollectable. The Company does not accrue interest receivable on past due accounts.
Revenue Recognition
Revenue from the sale of the Company’s products is recognized upon shipment of such products to its customers. The Company recognizes revenue from contracts on a straight line basis, over the terms of the contract. The Company recognizes revenue from grants based on the grant agreement, at the time the expenses are incurred.
Deferred Revenue
The Company defers payments received as revenue until earned based on the related contracts on a straight line basis, over the terms of the contract.
Income Taxes
The Company accounts for income taxes in accordance with the liability method. Under the liability method, the Company recognizes deferred assets and liabilities based upon anticipated future tax consequences attributable to differences between financial statement carrying amounts of assets and liabilities and their respective tax bases. The Company establishes a valuation allowance to the extent that it is more likely than not that deferred tax assets will not be utilized against future taxable income. As of December 31, 2013, the Company had approximately $59.8 million of net operating loss (“NOL”) carry forward. There was no provision for income taxes at March 31, 2014. A full valuation allowance has been recorded related to any deferred tax assets created from the NOL.
Stock Option Plan
The Company measures the cost of employees services received in exchange for equity awards, including stock options, based on the grant date fair value of the awards. The cost will be recognized as compensation expense over the vesting period of the awards.
Warrants
The Company has issued warrants, which allow the warrant holder to purchase one share of stock at a specified price for a specified period of time. The Company records equity instruments including warrants issued to non-employees based on the fair value at the date of issue. The fair value of warrants classified as equity instruments at date of issuance is estimated using the Black-Scholes Model. The fair value of warrants classified as liabilities at the date of issuance is estimated using the Monte Carlo Simulation model.
| 8 |
3. FAIR VALUE OF FINANCIAL INSTRUMENTS
The guidance for fair value measurements, ASC820, Fair Value Measurements and Disclosures, establishes the authoritative definition of fair value, sets out a framework for measuring fair value, and outlines the required disclosures regarding fair value
measurements. Fair value is the price that would be received to sell an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. The Company uses a three-tier fair value hierarchy based upon observable and non-observable inputs as follow:
| · | Level 1 – Quoted market prices in active markets for identical assets and liabilities; |
| · | Level 2 – Inputs, other than level 1 inputs, either directly or indirectly observable; and |
| · | Level 3 – Unobservable inputs developed using internal estimates and assumptions (there is little or no market date) which reflect those that market participants would use. |
The Company records its derivative activities at fair value, which consisted of warrants as of March 31, 2014. The fair value of the warrants was estimated using the Monte Carlo Simulation model. Gains and losses from derivative contracts are included in net gain (loss) from derivative contracts in the statement of operations. The fair value of the Company’s derivative warrants is classified as a Level 3 measurement, since unobservable inputs are used in the valuation.
The following table presents the fair value for those liabilities measured on a recurring basis as of March 31, 2014 and December 31, 2013:
FAIR VALUE MEASUREMENTS ( In Thousands)
| Description | Level 1 | Level 2 | Level 3 | Total | Asset/(Liability) Total |
||||||||||||||||||||
| Warrants | $ | — | $ | — | $ | (1,548 | ) | $ | (1,548 | ) | $ | (1,548 | ) | December 31, 2013 | |||||||||||
| Warrants | $ | — | $ | — | $ | (1,007 | ) | $ | (1,007 | ) | $ | (1,007 | ) | March 31, 2014 | |||||||||||
4. STOCK OPTIONS
The Company records compensation expense related to options granted to non-employees based on the fair value of the award.
Compensation cost is recorded as earned for all unvested stock options outstanding at the beginning of the first year based upon the grant date fair value estimates, and for compensation cost for all share-based payments granted or modified subsequently, based on fair value estimates.
For the quarter ended March 31, 2014 and 2013, stock-based compensation for options attributable to employees, officers and directors was approximately $298,000 and $430,000, respectively. Compensation costs for stock options, which vest over time, are recognized over the vesting period. As of March 31, 2014, the Company had approximately $1.5 million of unrecognized compensation cost related to granted stock options, to be recognized over the remaining vesting period of approximately three years.
The Company has a 1995 stock option plan (the “Plan”) approved by its stockholders for officers, directors and key employees of the Company and consultants to the Company. Participants are eligible to receive incentive and/or nonqualified stock options. The aggregate number of shares that may be granted under the Plan is 13,255,219 shares. The Plan is administered by the compensation committee of the board of directors. The selection of participants, grant of options, determination of price and other conditions relating to the exercise of options are determined by the compensation committee of the board of directors and administered in accordance with the Plan.
Both incentive stock options and non-qualified options granted to employees, officers and directors under the Plan are exercisable for a period of up to 10 years from the date of grant, at an exercise price that is not less than the fair market value of the common stock on the date of the grant. The options typically vest in installments of 1/48 of the options outstanding every month. Certain option granted to management vest based upon market and performance conditions.
A summary of the Company’s activity under the Plan as of March 31, 2014 and changes during the three months then ended is as follows:
| 9 |
|
Shares |
Weighted average exercise price |
Weighted average remaining contractual (years) |
Aggregate intrinsic value (thousands) | ||||
| Outstanding, January 1, 2014 | 6,531,192 | $ 0.66 | 6.97 | $ 625,412 | |||
| Granted | 2,109,511 | 0.51 | |||||
| Exercised / Expired | (220,000) | 0.30 | |||||
| Outstanding, March 31, 2014 | 8,420,703 | $ 0.63 | 6.97 | $ 558,747 | |||
| Vested and exercisable, March 31, 2014 | 5,771,724 | $ 0.61 | 5.85 | $ 558,747 |
The Company estimates the fair value of stock options using a Black-Scholes and Lattice valuation models. Key input assumptions used to estimate the fair value of stock options include the expected term, expected volatility of the Company’s stock, the risk free interest rate, option forfeiture rates, and dividends, if any. The expected term of the options is based upon the historical term until exercise or expiration of all granted options. The expected volatility is derived from the historical volatility of the Company’s stock on the OTCBB market for a period that matches the expected term of the option. The risk-free interest rate is the constant maturity rate published by the U.S. Federal Reserve Board that corresponds to the expected term of the option.
5. LITIGATION AND CLAIMS
From time to time, the Company may be involved in various legal proceedings and claims arising in the ordinary course of business. Management believes that the dispositions of these matters, individually or in the aggregate, are not expected to have a material adverse effect on the Company’s financial condition. However, depending on the amount and timing of such disposition, an unfavorable resolution of some or all of these matters could materially affect the future results of operations or cash flows in a particular period.
As of March 31, 2014 and December 31, 2013, there was no accrual recorded for any potential losses related to pending litigation.
6. STOCKHOLDERS' EQUITY
Common Stock
The Company has authorized 145 million shares of common stock with $0.001 par value, 71,770,239 of which were outstanding as of March 31, 2014. During the three months ended March 31, 2014, the Company issued 220,000 shares in connection with the exercise of outstanding options.
For the three months ended March 31, 2014, the Company issued 1,025,002 shares of common stock for its Series B preferred stock conversion, as well as 46,276 shares of common stock as payment of accrued dividends on the Series B preferred stock.
Preferred Stock; Series B Convertible Preferred Stock
The Company has authorized 5,000,000 shares of preferred stock with a $.001 par value. The board of directors has the authority to issue these shares and to set dividends, voting and conversion rights, redemption provisions, liquidation preferences, and other rights and restrictions. The board of directors designated 525,000 shares of preferred stock as redeemable convertible preferred stock, none of which remain outstanding, and 3,000 shares of preferred stock as Series B Preferred Stock, of which 1,737 and 2,147 shares were issued and outstanding as of March 31, 2014 and December 31, 2013 respectively.
Pursuant to the terms of the Series B Preferred Stock set forth in the Certificate of Designations, Preferences and Rights designating the Preferred Stock (the “Preferred Stock Designation”), shares of Series B Preferred Stock are convertible into common stock by their holder at any time, and will be mandatorily convertible upon the achievement of certain conditions, including the receipt of certain approvals from the U.S. Food and Drug Administration and the achievement by the Company of specified average trading prices and volumes for the common stock. The original conversion price was $0.68 per share, such that each share of Preferred Stock would convert into 1,471 shares of common stock, subject to customary adjustments, including any accrued but unpaid dividends and pursuant to certain anti-dilution provisions, as set forth in the Preferred Stock Designation. As a result of anti-dilution provisions, the current conversion price is set at $0.40 per share, such that each share of Preferred Stock would convert into 2,500 shares of common stock.
| 10 |
Holders of the Series B Preferred Stock are entitled to quarterly dividends at an annual rate of 10.0%, payable in cash or, subject to certain conditions, common stock, at the Company’s option. Accrued dividends totaled approximately $53,000 at March 31, 2014. Each share of Series B Preferred Stock is entitled to a number of votes equal to the number of shares of common stock into which the Series B Preferred Stock is convertible. As long as shares of the Series B Preferred Stock are outstanding, and until the receipt of certain approvals from the U.S. Food and Drug Administration and the achievement by the Company of specified average trading prices and volumes for the common stock, the Company may not incur indebtedness for borrowed money secured by the Company’s intellectual property or in excess of $2.0 million without the prior consent of the holders of two-thirds of the outstanding shares of Series B Preferred Stock. The Company may redeem the Series B Preferred Stock after the second anniversary of issuance, subject to certain conditions. Upon the Company’s liquidation or sale to or merger with another corporation, each share of Series B Preferred Stock will be entitled to a liquidation preference of $1,000 per share, plus any accrued but unpaid dividends.
The Series B Preferred Stock was issued with Tranche A warrants to purchase 1,858,089 shares of common stock and Tranche B warrants purchasing 1,858,088 shares of common stock, both at an exercise price of $1.08 per share. Pursuant to the terms of the Tranche B warrants, their exercise price will be reduced, and the number of shares of common stock into which those warrants are exercisable will be increased, if the Company issues shares at a price below the then-current exercise price. The exercise price of Tranche B warrants is currently $0.40 per share, convertible into 5,016,840 shares of common stock. As a result of these provisions, the Company is required to account for the warrants as a liability recorded at fair value each period. The Company values the warrants using a Monte Carlo Simulation model. Of the $2.6 million in proceeds from issuance of the Series B Preferred Stock, the Company originally allocated $873,000 to the fair value of the warrants. At March 31, 2014 and December 31, 2013, the fair value of these warrants was approximately $1.0 million and $1.5 million, respectively.
Stock Options
See Note 4, Stock Options.
Warrants
We have issued warrants to purchase our common stock from time to time in connection with certain financing arrangements.
The Company had the following shares reserved for the warrants as of March 31, 2014:
| Warrants (Underlying Shares) |
Exercise Price | Expiration Date | ||
| 471,856 | (1) | $0.80 per share | July 26, 2014 | |
| 3,590,522 | (1) | $0.80 per share | March 1, 2015 | |
| 6,790 | (2) | $1.01 per share | September 10, 2015 | |
| 439,883 | (3) | $0.68 per share | March 31, 2016 | |
| 285,186 | (4) | $1.05 per share | November 20, 2016 | |
| 1,858,089 | (5) | $1.08 per share | May 23, 2018 | |
| 5,016,840 | (6) | $0.40 per share | May 23, 2018 |
__________
(1) Consists of outstanding warrants issued in connection with a warrant exchange program in June 2012.
| (2) | Consists of outstanding warrants issued in conjunction with a private placement on September 10, 2010. |
| (3) | Consists of outstanding warrants issued in conjunction with a buy back of our minority interest in our subsidiary in December 2012, which were issued in February 2014. |
| (4) | Consists of outstanding warrants issued in conjunction with a private placement on November 21, 2011. |
| (5) | Consists of outstanding warrants issued in conjunction with a private placement on May 24, 2013. |
| (6) | Consists of outstanding warrants issued in conjunction with a private placement on May 24, 2013. Underlying shares increased from 1,858,089 to 5,016,840, and exercise price decreased from $1.08 per share to $0.40 per share, pursuant to the terms of the warrants, as a result of a 2013 warrant exchange program. |
7. LOSS PER COMMON SHARE
Basic net loss per share attributable to common stockholders amounts are computed by dividing the net loss plus preferred stock dividends and deemed dividends on preferred stock by the weighted average number of common shares outstanding during the period.
| 11 |
8. NOTES PAYABLE
Short Term Notes Payable
At March 31, 2014, the Company maintained notes payable and accrued interest to related parties totaling $177,000 and third parties totaling $ 201,000. These notes are short term, straight-line amortizing notes. The notes carry an annual interest rate of 10%.
Notes Payable
At December 31, 2012, the Company was past due on two short-term notes totaling approximately $419,000 of principal and accrued interest. Interest charged on these notes prior to amendment ranged between 15-18%. On February 27, 2013, the Company renegotiated one of the two past due notes. The new note accrued interest at 6% and was paid in full during the quarter ended June 30, 2013. On April 16, 2013, the Company renegotiated the other note. The renegotiated note accrues interest at 9.0%, with a 16.0% default rate, requires monthly payments of $10,000, including interest, and matures November 2015. The balance due on this note was approximately $203,000 and $208,000 at March 31, 2014 and December 31, 2013, respectively. As of March 31, 2014, the note is accruing interest at the default rate, of which $63,000 is payable during the year ending December 31, 2014 and $105,000 is payable during the year ending December 31, 2015.
8. SUBSEQUENT EVENTS
On April 23, 2014, the Company entered into a securities purchase agreement (the “Purchase Agreement”), with Hanover Holdings I, LLC, an affiliate of Magna Group (“Magna”). Pursuant to the Purchase Agreement, the Company sold Magna a senior convertible note with an initial principal amount of $1.5 million (the “Initial Convertible Note”), for a purchase price of $1.0 million (an approximately 33.3% original issue discount). Additionally, Magna is irrevocably bound to purchase, on the tenth trading day after the effective date of a resale registration statement, an additional senior convertible note with an initial principal amount of $2.0 million and an 18-month term (the “Additional Convertible Note” and, with the Initial Convertible Note, the “Convertible Notes”), for a fixed purchase price of $2.0 million, subject only to conditions outside of Magna’s control or that Magna cannot cause not to be satisfied, none of which are related to the market price of the Company’s common stock.
With respect to the Initial Convertible Note, $200,000 of the outstanding principal amount (together with any accrued and unpaid interest with respect to such portion of the principal amount) was automatically extinguished (without any cash payment by the Company) once the Company properly filed a registration statement with the SEC on April 30, 2014 covering the resale by Magna of shares of the Company’s common stock issued or issuable upon conversion of the Convertible Notes and (2) no event of default, or an event that with the passage of time or giving of notice would constitute an event of default, had occurred on or prior to such date. Moreover, $300,000 of the outstanding principal amount of the Initial Convertible Note (together with any accrued and unpaid interest with respect to such portion of the principal amount) was automatically extinguished (without any cash payment by the Company) once the resale registration statement was declared effective by the SEC on May 12, 2014 and the prospectus contained therein became available for use by Magna for its resale of the shares of common stock issued or issuable upon conversion of the Convertible Notes and (2) no event of default, or an event that with the passage of time or giving of notice would constitute an event of default, had occurred on or prior to such date.
The Initial Convertible Note matures on October 23, 2015 (subject to extension as provided in the Initial Convertible Note) and, in addition to the approximately 33.3% original issue discount, accrues interest at an annual rate of 6.0%. If issued, the Additional Convertible Note will mature 18 months from the date of issuance and will accrue interest at the same rate. The Convertible Notes are convertible at any time, in whole or in part, at Magna’s option, into shares of the Company’s common stock, at a conversion price equal to the lesser of $0.55 per share and a discount from the lowest daily volume-weighted average price of the Company’s common stock in the five trading days prior to conversion. The discount is 20% if the conversion takes place prior to December 19, 2014, and 25% if after that date. At no time will Magna be entitled to convert any portion of the Convertible Notes to the extent that after such conversion, Magna (together with its affiliates) would beneficially own more than 9.99% of the outstanding shares of the Company’s common stock as of such date. As long as Magna or its affiliates beneficially own any of the shares issued upon conversion, they may not engage in any “short sale” transactions in the Company’s common stock and may not sell more than the greater of $15,000 or 15% of the trading volume of the common stock in any single trading day.
| 12 |
The Initial Convertible Note includes and, if issued, the Additional Convertible Note will include, customary event of default provisions. The Initial Convertible Note provides and, if issued, the Additional Convertible Note will provide for a default interest rate of 16%. Upon the occurrence of an event of default, Magna may require the Company to pay in cash the “Event of Default Redemption Price” which is defined in the Convertible Notes to mean the greater of (i) the product of (A) the amount to be redeemed multiplied by (B) 135% (or 100% if an insolvency related event of default) and (ii) the product of (X) the conversion price in effect at that time multiplied by (Y) the product of (1) 135% (or 100% if an insolvency related event of default) multiplied by (2) the greatest closing sale price of the common stock on any trading day during the period commencing on the date immediately preceding such event of default and ending on the date the Company makes the entire payment required to be made under this provision.
The Company has the right at any time to redeem all or a portion of the total outstanding amount then remaining under the Convertible Notes in cash at a 25% premium.
The Company paid to Magna a commitment fee for entering into the Purchase Agreement equal to 5% of the total purchase price for the Convertible Notes under the Purchase Agreement in the form of 321,820 shares of common stock (the “Commitment Shares”), calculated using a per share price of $0.465, representing the average of the daily volume-weighted average prices of a share of common stock for the second trading day immediately preceding closing date for the transaction. The Company also paid $50,000 of reasonable attorneys’ fees and expenses incurred by Magna in connection with the transaction.
The Purchase Agreement contains customary representations, warranties and covenants by, among and for the benefit of the parties. The Purchase Agreement also provides for indemnification of Magna and its affiliates in the event that Magna incurs losses, liabilities, obligations, claims, contingencies, damages, costs and expenses related to the Company’s breach of any of its representations, warranties or covenants under the Purchase Agreement.
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Statements in this report which express "belief," "anticipation" or "expectation," as well as other statements which are not historical facts, are forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from historical results or anticipated results, including those that may be set forth under "Risk Factors" below and elsewhere in this report, as well as in our annual report on Form 10-K for the year ended December 31, 2013 and subsequently filed quarterly reports on Form 10-Q. Examples of these uncertainties and risks include, but are not limited to:
|
· |
access to sufficient debt or equity capital to meet our operating and financial needs; | |
| · | the effectiveness and ultimate market acceptance of our products; | |
| · | whether our products in development will prove safe, feasible and effective; | |
| · | whether and when we or any potential strategic partners will obtain approval from the FDA and corresponding foreign agencies; | |
| · | our need to achieve manufacturing scale-up in a timely manner, and our need to provide for the efficient manufacturing of sufficient quantities of our products; | |
| · | the lack of immediate alternate sources of supply for some critical components of our products; | |
| · | our patent and intellectual property position; | |
| · | the need to fully develop the marketing, distribution, customer service and technical support and other functions critical to the success of our product lines; | |
| · | the dependence on potential strategic partners or outside investors for funding, development assistance, clinical trials, distribution and marketing of some of our products; and | |
| · | other risks and uncertainties described from time to time in our reports filed with the SEC. |
The following discussion should be read in conjunction with our financial statements and notes thereto included elsewhere in this report.
OVERVIEW
We are a medical technology company focused on developing innovative medical devices that have the potential to improve healthcare. Our primary focus is the development of our LuViva non-invasive cervical cancer detection device and extension of our cancer detection technology into other cancers, including lung and esophageal. Our technology, including products in research and development, primarily relates to biophotonics technology for the non-invasive detection of cancers.
We are a Delaware corporation, originally incorporated in 1992 under the name “SpectRx, Inc.,” and, on February 22, 2008, changed our name to Guided Therapeutics, Inc. At the same time, we renamed our majority owned subsidiary, InterScan, which originally had been incorporated as “Guided Therapeutics.”
| 13 |
Since our inception, we have raised capital through the private sale of preferred stock and debt securities, public and private sales of common stock, funding from collaborative arrangements and grants.
Our prospects must be considered in light of the substantial risks, expenses and difficulties encountered by entrants into the medical device industry. This industry is characterized by an increasing number of participants, intense competition and a high failure rate. We have experienced operating losses since our inception and, as of March 31, 2014, we had an accumulated deficit of about $104.6 million. To date, we have engaged primarily in research and development efforts. We do not have significant experience in manufacturing, marketing or selling our products. Our development efforts may not result in commercially viable products and we may not be successful in introducing our products. Moreover, required regulatory clearances or approvals may not be obtained in a timely manner, or at all. Our products may not ever gain market acceptance and we may not ever generate significant revenues or achieve profitability. The development and commercialization of our products requires substantial development, regulatory, sales and marketing, manufacturing and other expenditures. We expect our operating losses to continue through at least the end of 2014 as we continue to expend substantial resources to introduce LuViva, further the development of our other products, obtain regulatory clearances or approvals, build our marketing, sales, manufacturing and finance organizations and conduct further research and development.
CRITICAL ACCOUNTING POLICIES
Our material accounting policies, which we believe are the most critical to an investors understanding of our financial results and condition, are discussed below. Because we are still early in our enterprise development, the number of these policies requiring explanation is limited. As we begin to generate increased revenue from different sources, we expect that the number of applicable policies and complexity of the judgments required will increase.
Currently, our policies that could require critical management judgment are in the areas of revenue recognition, reserves for accounts receivable and inventory valuation.
Revenue Recognition: We recognize revenue from contracts on a straight line basis, over the terms of the contract. We recognize revenue from grants based on the grant agreement, at the time the expenses are incurred. Revenue from the sale of the Company’s products is recognized upon shipment of such products to its customers.
Valuation of Deferred Taxes: We account for income taxes in accordance with the liability method. Under the liability method, we recognize deferred assets and liabilities based upon anticipated future tax consequences attributable to differences between financial statement carrying amounts of assets and liabilities and their respective tax bases. We establish a valuation allowance to the extent that it is more likely than not that deferred tax assets will not be utilized against future taxable income.
Stock Option Plan: We measure the cost of employees services received in exchange for equity awards, including stock options, based on the grant date fair value of the awards. The cost will be recognized as compensation expense over the vesting period of the awards.
Warrants: We have issued warrants, which allow the warrant holder to purchase one share of stock at a specified price for a specified period of time. We record equity instruments, including warrants issued to non-employees, based on the fair value at the date of issue. The fair value of the warrants, at date of issuance, is estimated using the Black-Scholes Model.
Allowance for Inventory Valuation: We estimate losses from obsolete and damaged inventories quarterly and revise our reserves as a result. Since the inventory is stated at the lower of cost or market, we also estimated an allowance for the potential losses on the sale of inventory.
Allowance for Accounts Receivable: We estimate losses from the inability of our customers to make required payments and periodically review the payment history of each of our customers, as well as their financial condition, and revise our reserves as a result.
RECENT DEVELOPMENTS
On April 23, 2014, we entered into a securities purchase agreement (the “Purchase Agreement”), with Hanover Holdings I, LLC, an affiliate of Magna Group (“Magna”). Pursuant to the Purchase Agreement, we sold Magna a senior convertible note with an initial principal amount of $1.5 million (the “Initial Convertible Note”), for a purchase price of $1.0 million (an approximately 33.3% original issue discount). Additionally, Magna is irrevocably bound to purchase, on the tenth trading day after the effective date of a resale registration statement, an additional senior convertible note with an initial principal amount of $2.0 million and an 18-month term (the “Additional Convertible Note” and, with the Initial Convertible Note, the “Convertible Notes”), for a fixed purchase price of $2.0 million, subject only to conditions outside of Magna’s control or that Magna cannot cause not to be satisfied, none of which are related to the market price of the Company’s common stock. See Note 8 to the financial statements accompanying this report.
| 14 |
RESULTS OF OPERATIONS
COMPARISON OF THE THREE MONTHS ENDED MARCH 31, 2014 AND 2013
Service Revenue: Service revenue decreased to approximately $19,000 for the quarter ended March 31, 2014, from approximately $167,000 for the same period in 2013. Service revenue was lower for the first quarter 2014 due to the decreased revenue from NCI and NIH during the three months then ended.
Sales Revenue, Cost of Sales and Gross Loss from Devices and Disposables: Sales revenue from the sale of LuViva devices and disposables for the three months ended March 31, 2014, was approximately $122,000. Related costs of sales and net realizable value expenses were approximately $192,000, which resulted in a gross loss on the device and disposables of approximately $70,000. Sales revenue from the sale of LuViva devices and disposables for the three months ended March 31, 2013, was approximately $132,000. Related costs of sales were approximately $158,000, which resulted in a gross loss on the device and disposables of approximately $26,000.
Research and Development Expenses: Research and development expenses decreased to approximately $607,000 for the three months ended March 31, 2014, compared to $813,000 for the same period in 2013. The decrease, of approximately $206,000, was primarily due to a decrease in expenses associated with our esophageal cancer technology and LuViva devices in production mode.
Sales and Marketing Expenses: Sales and marketing expenses were approximately $283,000 during the three months ended March 31, 2014, compared to $164,000 for the same period in 2013. The increase was primarily due to efforts underway in marketing our cervical cancer detection product.
General and Administrative Expenses: General and administrative expenses increased to approximately $1.1 million during the three months ended March 31, 2014, compared to approximately $1.0 million for the same period in 2013. The increase of approximately $99,000, or 9.5%, is primarily related to increase in general operating expenses.
Other Income: Other income for the three months ended March 31, 2014, was approximately $2,000, which represents miscellaneous income and receipts; compared to other income of approximately $75,000 for the three months ended March 31, 2013. Other income in the three months ended March 31, 2013, consists of a one-time payment from our previous insurance company for policy dividends.
Interest Expense: Interest expense increased to approximately $27,000 for the three months ended March 31, 2014, as compared to approximately $15,000 for the same period in 2013, primarily due to accrued interest on our short term notes payable.
Fair Value of Warrants Expense: Fair value of warrants expense recovery was approximately $541,000 for the year three months ended March 31, 2014, as compared to none for the same period in 2013.
Net loss was approximately $1.6 million during the three months ended March 31, 2014, compared to $1.8 million for the same period in 2013, for the reasons outlined above.
LIQUIDITY AND CAPITAL RESOURCES
Since our inception, we have raised capital through the private sale of preferred stock and debt securities, public and private sales of common stock, funding from collaborative arrangements, and grants. At March 31, 2014, we had cash of approximately $50,000 and negative working capital of approximately $1.3 million.
Our major cash flows in the quarter ended March 31, 2014, consisted of cash out-flows of approximately $959,000 million from operations, including approximately $1.6 million of net loss, cash outflow of $4,000 from investing activities and a net change from financing activities of $400,000, which primarily represents the proceeds received from the short term notes payables and exercise of outstanding options, offset in part by cash utilized for loan repayment.
| 15 |
On May 23, 2013, we completed a private placement of our Series B Preferred Stock and warrants to purchase shares of our common stock. We issued an aggregate of 2,527 shares of Series B Preferred Stock at a purchase price of $1,000 per share. The initial conversion price of the Series B Preferred Stock was $0.68 per share, such that each share would convert into 1,471 shares of our common stock, subject to customary adjustments, including for any accrued but unpaid dividends and pursuant to certain anti-dilution provisions. We also issued warrants, on a pro rata basis to the investors, exercisable to purchase an aggregate of 3,716,177 shares of our common stock. The warrants, which carry a five-year term, were split evenly into two tranches, one of which is subject to a mandatory exercise provision. The warrants are exercisable at any time and had an initial exercise price of $1.08 per share, subject to certain customary adjustments contained in the respective warrants. As a result of the November 2013 warrant exchange program described below, the conversion price of the Series B Preferred Stock has been lowered to $0.40 per share, such that each share is now convertible into 2,500 shares of common stock, and one tranche of the warrants, previously exercisable for 1,858,089 shares of common stock at $1.08 per share, is now exercisable for 5,016,840 shares at $0.40 per share.
In November 2013, we completed another warrant exchange program pursuant to which we exchanged warrants exercisable for a total of 3,573,691 shares of common stock, or 99.5% of the warrants eligible to participate, for new warrants exercisable for the same number of shares of common stock, but with a reduced exercise price of $0.40 per share and a shortened exercise period ending on November 27, 2013. As of December 31, 2013, we had issued 3,399,965 shares of common stock and received approximately $1.4 million in cash in connection with the exercise of these new warrants.
We will be required to raise additional funds through public or private financing, additional collaborative relationships or other arrangements. We believe our existing and available capital resources will be sufficient to satisfy our funding requirements through the second quarter of 2014. We are evaluating various options to further reduce our cash requirements to operate at a reduced rate, as well as options to raise additional funds, including loans.
Substantial capital will be required to develop our products, including completing product testing and clinical trials, obtaining all required U.S. and foreign regulatory approvals and clearances, and commencing and scaling up manufacturing and marketing our products. Any failure to obtain capital would have a material adverse effect on our business, financial condition and results of operations.
Our financial statements have been prepared and presented on a basis assuming we will continue as a going concern. The above factors raise substantial doubt about our ability to continue as a going concern, as more fully discussed in Note 1 to the consolidated financial statements contained herein and in the report of our independent registered public accounting firm accompanying our financial statements contained in our annual report on Form 10-K for the year ended December 31, 2013.
Off-Balance Sheet Arrangements
We have no material off-balance sheet arrangements, no special purpose entities, and no activities that include non-exchange-traded contracts accounted for at fair value.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
Not applicable.
ITEM 4. CONTROLS AND PROCEDURES
Disclosure Controls and Procedures
The Company under the supervision and with the participation of management, including the Chief Executive Officer (principal executive officer) and the Chief Financial Officer (principal financial officer), evaluated the effectiveness of our “disclosure controls and procedures” (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934 (the “Exchange Act”)) as of March 31, 2014. The controls and System currently used by the Company to calculate and record inventory is not operating effectively. Additionally, the Company lacks the resources to properly research and account for complex transactions. The combination of these controls deficiencies have resulted in a material weakness in our internal control over financial reporting.
Based on that evaluation, the Chief Executive Officer and the Chief Financial Officer concluded that our disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) were not effective as of March 31, 2014 to provide reasonable assurance that (1) information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms, and (2) information required to be disclosed by us in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosures.
| 16 |
The effectiveness of any system of controls and procedures is subject to certain limitations, and, as a result, there can be no assurance that our controls and procedures will detect all errors or fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system will be attained.
Changes in Internal Control Over Financial Reporting
There has been no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended March 31, 2014 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
| 17 |
PART II - OTHER INFORMATION
ITEM 1. LEGAL PROCEDINGS
From time to time, the Company may be involved in various legal proceedings and claims arising in the ordinary course of business. Management believes that the disposition of these matters, individually or in the aggregate, is not expected to have a material adverse effect on the Company’s financial condition. See Note 5 to the financial statements that a
ITEM 1A. RISK FACTORS
Please refer to Part I, Item 1A, “Risk Factors,” in our annual report on Form 10-K for the year ended December 31, 2013, for information regarding factors that could affect our results of operations, financial condition and liquidity.
ITEM 2. UNREGISTERRED SALES OF EQUITY PROCEEDS AND USE OF PROCEEDS.
During the three months ended March 31, 2013, the Company issued 670,313 shares to its directors as compensation for board services. The issuance of shares was exempt from registration under the Securities Act in reliance upon Section 4(a)(2) of the Securities Act as a transaction by an issuer not involving a public offering. The shares are restricted securities for purposes of the Securities Act. Certificates representing the shares being a restrictive legend providing that the shares have not been registered under the Securities Act and cannot be sold or otherwise transferred without an effective registration or exemption therefrom. The Company received no cash proceeds from the issuances.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
Not applicable.
ITEM 4. MINE SAFETY DISCLOSURES
Not applicable.
ITEM 5. OTHER INFORMATION
Not applicable.
ITEM 6. EXHIBITS
EXHIBIT INDEX
EXHIBITS
| Exhibit Number | Exhibit Description |
| 31 | Rule 13a-14(a)/15d-14(a) Certification |
| 32 | Section 1350 Certification |
| 101 | XBRL |
| 18 |
SIGNATURES
In accordance with the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| GUIDED THERAPEUTICS, INC. | |
|
/s/ Gene S. Cartwright | |
|
By: |
Gene S. Cartwright |
| President, Chief Executive Officer and | |
| Acting Chief Financial Officer | |
|
Date: |
May 15, 2014 |
| 19 |
Exhibit 31
Rule 13a-14(a) / 15(d)-14(a) Certification
I, Gene S. Cartwright, certify that:
| 1. | I have reviewed this quarterly report on Form 10-Q of Guided Therapeutics, Inc. for the quarter ending March 31, 2014; |
| 2. | Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report; |
| 3. | Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report; |
| 4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15 (f) for the registrant and have: |
| a. | designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared. |
| b. | designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
| c. | evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
| d. | disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and |
| 5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and audit committee of the registrant's board of directors (or persons performing the equivalent functions): |
| a. | all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and |
| b. | any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |
| Date: May 15, 2014 |
/s/ Gene S. Cartwright Gene S. Cartwright Chief Executive Officer, President and acting Chief Financial Officer |
EXHIBIT 32
SECTION 1350 CERTIFICATION
In connection with the Quarterly Report of Guided Therapeutics, Inc. (the "Company") on Form 10-Q for the quarter ended March 31, 2014, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), I, Gene S. Cartwright, President, Chief Executive Officer and acting Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Sec. 1350, as adopted pursuant to Sec 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge and belief:
| (1) | the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
| (2) |
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: May 15, 2014
| /s/ Gene S. Cartwright |
| Name: Gene S. Cartwright |
| Title: President, Chief Executive Officer and acting Chief Financial Officer |
.K-^XT1RL7_97/)=3X
MRB?3^3?)])5#E;=W2"(KHKTHO_IR@)'6IU6U<^%D>,7GN+'_?MI*ELR@28YO
M7X0C@G9V8L:*8Z,(-5NMJ+_PW8%N,IBM=^_'=],\R_1OYMF+E:\NCX